US5977144A
(en)
*
|
1992-08-31 |
1999-11-02 |
University Of Florida |
Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines
|
US5852041A
(en)
*
|
1993-04-07 |
1998-12-22 |
Sibia Neurosciences, Inc. |
Substituted pyridines useful as modulators of acethylcholine receptors
|
US5731314A
(en)
*
|
1995-01-06 |
1998-03-24 |
Bencherif; Merouane |
Pharamceutical compositions for prevention and treatment of tourette's syndrome
|
US5824692A
(en)
*
|
1995-01-06 |
1998-10-20 |
Lippiello; Patrick Michael |
Pharmaceutical compositions for prevention and treatment of central nervous system disorders
|
US5616707A
(en)
*
|
1995-01-06 |
1997-04-01 |
Crooks; Peter A. |
Compounds which are useful for prevention and treatment of central nervous system disorders
|
WO1996020600A1
(en)
*
|
1995-01-06 |
1996-07-11 |
R.J. Reynolds Tobacco Company |
Pharmaceutical compositions for prevention and treatment of central nervous system disorders
|
US5597919A
(en)
*
|
1995-01-06 |
1997-01-28 |
Dull; Gary M. |
Pyrimidinyl or Pyridinyl alkenyl amine compounds
|
US6194581B1
(en)
|
1995-04-07 |
2001-02-27 |
Merck & Co., Inc. |
Substituted pyridines useful as modulators of acetylcholine receptors
|
US5585388A
(en)
*
|
1995-04-07 |
1996-12-17 |
Sibia Neurosciences, Inc. |
Substituted pyridines useful as modulators of acetylcholine receptors
|
US5583140A
(en)
*
|
1995-05-17 |
1996-12-10 |
Bencherif; Merouane |
Pharmaceutical compositions for the treatment of central nervous system disorders
|
US5794887A
(en)
|
1995-11-17 |
1998-08-18 |
Komerath; Narayanan M. |
Stagnation point vortex controller
|
US5616716A
(en)
*
|
1996-01-06 |
1997-04-01 |
Dull; Gary M. |
(3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
|
US5663356A
(en)
*
|
1996-04-23 |
1997-09-02 |
Ruecroft; Graham |
Method for preparation of aryl substituted alefinic secondary amino compounds
|
US20020052497A1
(en)
*
|
2000-03-09 |
2002-05-02 |
Targacept, Inc. |
Compounds capable of activating cholinergic receptors
|
CA2252515C
(en)
|
1996-04-23 |
2006-11-07 |
R.J. Reynolds Tobacco Company |
Pharmaceutical compositions for prevention and treatment of central nervous system disorders
|
US6166048A
(en)
|
1999-04-20 |
2000-12-26 |
Targacept, Inc. |
Pharmaceutical compositions for inhibition of cytokine production and secretion
|
US6979695B2
(en)
*
|
1996-04-23 |
2005-12-27 |
Targacept, Inc. |
Compounds capable of activating cholinergic receptors
|
US6531606B1
(en)
*
|
1997-02-21 |
2003-03-11 |
Targacept, Inc. |
Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds
|
US5861423A
(en)
*
|
1997-02-21 |
1999-01-19 |
Caldwell; William Scott |
Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds
|
US5811442A
(en)
*
|
1997-02-21 |
1998-09-22 |
Bencherif; Merouane |
Pharmaceutical compositions for the treatment of conditions associated with decreased blood flow
|
US7214686B2
(en)
*
|
1997-06-30 |
2007-05-08 |
Targacept, Inc. |
Pharmaceutical compositions and methods for effecting dopamine release
|
BR9908190A
(pt)
*
|
1998-02-24 |
2000-10-24 |
Univ Wake Forest |
Processos para tratar a dor especìfica de fêmea em um paciente fêmea, e para tratar a dor crÈnica em um paciente
|
JP2002510619A
(ja)
|
1998-04-02 |
2002-04-09 |
アール・ジェイ・レイノルズ・タバコ・カンパニー |
薬剤組成物及びその使用法
|
US7790757B2
(en)
*
|
1998-06-16 |
2010-09-07 |
Targacept, Inc. |
Compounds capable of activating cholinergic receptors
|
US20050131034A1
(en)
*
|
1998-06-16 |
2005-06-16 |
Caldwell William S. |
Compounds capable of activating cholinergic receptors
|
US6232316B1
(en)
|
1998-06-16 |
2001-05-15 |
Targacept, Inc. |
Methods for treatment of CNS disorders
|
US6218383B1
(en)
|
1998-08-07 |
2001-04-17 |
Targacept, Inc. |
Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
|
US6262124B1
(en)
|
1998-10-22 |
2001-07-17 |
Gary Maurice Dull |
Pharmaceutical compositions and methods for use
|
US6432975B1
(en)
|
1998-12-11 |
2002-08-13 |
Targacept, Inc. |
Pharmaceutical compositions and methods for use
|
US6953855B2
(en)
*
|
1998-12-11 |
2005-10-11 |
Targacept, Inc. |
3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
|
US20010031771A1
(en)
|
1999-05-24 |
2001-10-18 |
Gary Maurice Dull |
Pharmaceutical compositions and methods for use
|
JP2003501416A
(ja)
*
|
1999-06-07 |
2003-01-14 |
ターガセプト,インコーポレイテッド |
医薬組成物およびその使用法
|
US6455554B1
(en)
|
1999-06-07 |
2002-09-24 |
Targacept, Inc. |
Oxopyridinyl pharmaceutical compositions and methods for use
|
US6890935B2
(en)
*
|
1999-11-01 |
2005-05-10 |
Targacept, Inc. |
Pharmaceutical compositions and methods for use
|
FR2810886B1
(fr)
*
|
2000-06-05 |
2002-12-27 |
Sanjuan Benito Arranz |
Dans le traitement des maladies neurodegeneratives : (notamment alzheimer et parkinson), utilisation pour un medicament : de la nicotine et du sildenafil (ou des derives des deux)
|
US6852741B2
(en)
|
2001-12-31 |
2005-02-08 |
University Of Florida |
Compositions and methods for treatment of neurological disorders
|
WO2004012674A2
(en)
*
|
2002-08-02 |
2004-02-12 |
Nutraceutical Development Corporation |
Development of muscle mass in a mammal
|
PT1678172E
(pt)
*
|
2003-10-15 |
2010-03-03 |
Targacept Inc |
Composições farmacêuticas e métodos para alívio da dor e tratamento de perturbações do sistema nervoso central
|
US20070191815A1
(en)
|
2004-09-13 |
2007-08-16 |
Chrono Therapeutics, Inc. |
Biosynchronous transdermal drug delivery
|
CA2563023C
(en)
*
|
2004-04-02 |
2012-01-24 |
Arterial Remodelling Technologies, Inc. |
Polymer-based stent assembly
|
US8252321B2
(en)
|
2004-09-13 |
2012-08-28 |
Chrono Therapeutics, Inc. |
Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
|
US7459469B2
(en)
|
2004-11-10 |
2008-12-02 |
Targacept, Inc. |
Hydroxybenzoate salts of metanicotine compounds
|
UA88792C2
(ru)
|
2004-11-10 |
2009-11-25 |
Таргасепт, Інк. |
Гидроксибензоатные соли метаникотиновых соединений
|
US8017785B2
(en)
*
|
2006-05-09 |
2011-09-13 |
Astrazeneca Ab |
Salt forms of (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)y1]-4-penten 2-amine
|
TWI389889B
(zh)
*
|
2006-05-09 |
2013-03-21 |
Targacept Inc |
(2s)-(4e)-n-甲基-5-〔3-(5-異丙氧基吡啶)基〕-4-戊烯-2-胺之新穎多晶型
|
CL2007002684A1
(es)
*
|
2006-09-15 |
2008-06-27 |
Astrazeneca Ab Targacept Inc |
Combinacion que comprende un antipsicotico y (2s)-(4e)-n-metil-5-[3-(5-isopropoxipiridin)il]-4-penten-2-amina; composicion farmaceutica que la comprende; kit farmaceutico; y uso para tratar perjuicio cognitivo y/o trastorno psicoticos.
|
US20100028447A1
(en)
*
|
2007-01-22 |
2010-02-04 |
Targacept, Inc. |
Intranasal, Buccal, And Sublingual Administration Of Metanicotine Analogs
|
GB2448224B
(en)
*
|
2007-04-02 |
2010-09-01 |
Parkinson S Inst |
Solid orally administered pharmaceutical composition for the reduction of side-effects of a dopaminergic agent
|
RU2010107278A
(ru)
*
|
2007-07-31 |
2011-09-10 |
Таргасепт, Инк. (Us) |
Трансдермальное введение (2s)-(4е)-n-метил-5-(3-(5-изопропоксипиридин)ил)-4-пентен-2-амина
|
SA08290475B1
(ar)
|
2007-08-02 |
2013-06-22 |
Targacept Inc |
(2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
|
TW201031664A
(en)
|
2009-01-26 |
2010-09-01 |
Targacept Inc |
Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
|
MX2012013193A
(es)
|
2010-05-20 |
2012-12-17 |
Astrazeneca Ab |
Nuevo proceso para preparar aminas olefinicas sustituidas con arilo.
|
WO2013006643A1
(en)
|
2011-07-06 |
2013-01-10 |
The Parkinson's Institute |
Compositions and methods for treatment of symptoms in parkinson's disease patients
|
CA2949395C
(en)
*
|
2014-05-16 |
2024-01-02 |
Synaptec Development Llc |
Clearance of amyloid.beta.
|
JP2018511355A
(ja)
|
2015-01-28 |
2018-04-26 |
クロノ セラピューティクス インコーポレイテッドChrono Therapeutics Inc. |
薬剤送達方法及びシステム
|
EP3267875A4
(de)
|
2015-03-12 |
2018-12-05 |
Chrono Therapeutics Inc. |
Eingabe- und unterstützungssystem für heftiges verlangen
|
US9724340B2
(en)
|
2015-07-31 |
2017-08-08 |
Attenua, Inc. |
Antitussive compositions and methods
|
EP3565617A1
(de)
|
2017-01-06 |
2019-11-13 |
Chrono Therapeutics Inc. |
Vorrichtungen und verfahren zur transdermalen wirkstofffreisetzung
|
AU2019279884A1
(en)
|
2018-05-29 |
2020-12-10 |
Morningside Venture Investments Limited |
Drug delivery methods and systems
|